Trial Profile
A phase III trial of vapendavir [BTA 798] for the treatment of naturally acquired human rhinovirus (HRV) infections in adults with asthma.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 29 Mar 2012
Price :
$35
*
At a glance
- Drugs Vapendavir (Primary)
- Indications Asthma; Rhinovirus infections
- Focus Therapeutic Use
- 29 Mar 2012 New trial record